- Genocea Biosciences (NASDAQ:GNCA) commences a Phase 2 dose optimization trial for GEN-003, its immunotherapy candidate for herpes simplex-type 2 (HSV-2). The 300-patient 17-site study will evaluate six combinations of two antigen doses (30 or 60 mcg) with each of three adjuvant doses alongside a placebo. All subjects will receive three doses of GEN-003 or placebo at 21-day intervals.
- The primary endpoint is the change in viral shedding rate from baseline.
- The company expects to announce interim results in mid-2015.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs